Authors: Depairon, M Chessex, S Sudre, P Rodondi, N Doser, N Chave, JP Riesen, W Nicod, P Darioli, R Telenti, A Mooser, V

Citation: M. Depairon et al., Premature atherosclerosis in HIV-infected individuals - focus on protease inhibitor therapy, AIDS, 15(3), 2001, pp. 329-334

Authors: Marzolini, C Chave, JP Telenti, A Brenas-Chinchon, L Biollaz, J

Citation: C. Marzolini et al., Impaired absorption of rifabutin by concomitant administration of didanosine, AIDS, 15(16), 2001, pp. 2203-2204

Authors: Yerly, S Kaiser, L Perneger, TV Cone, RW Opravil, M Chave, JP Furrer, H Hirschel, B Perrin, L

Citation: S. Yerly et al., Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia, AIDS, 14(3), 2000, pp. 243-249

Authors: Bart, PA Rizzardi, GP Tambussi, G Chave, JP Chapuis, AG Graziois, C Corpataux, JM Halkic, N Meuwly, JY Munoz, M Meylan, P Spreen, W McDade, H Yerly, S Perrin, L Lazzarin, A Pantaleo, G

Citation: Pa. Bart et al., Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy, AIDS, 14(13), 2000, pp. 1887-1897

Authors: Lorenzi, P Opravil, M Hirschel, B Chave, JP Furrer, HJ Sax, H Perneger, TV Perrin, L Kaiser, L Yerly, S

Citation: P. Lorenzi et al., Impact of drug resistance mutations on virologic response to salvage therapy, AIDS, 13(2), 1999, pp. F17-F21